secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0000914121-22-004104
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook
--------------------------------------------------------------------------------

- Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.
- Med Tech net sales $22.8M (+29.6%), driven by Auryon (+50.0%) and thrombectomy (+31.8%); Med Device declined 1.1% to $58.7M.
- Gross margin 51.9% down 20 bps; adjusted loss per share $0.06 vs $0.02 in prior year.
- FY2023 guidance reaffirmed: net sales $342-348M, gross margin 52.5%-54.5%, adjusted EPS $0.01-$0.06.
- New $75M credit facility with $30M term loan (drawn $25M); cash $24.6M; AlphaVac F18 full market release commenced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122004104/0000914121-22-004104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122004104/an58259826-8ki.htm
  HTML page:      https://secwatch.observer/filing/0000914121-22-004104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer